Tags

Type your tag names separated by a space and hit enter

Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Front Immunol. 2018; 9:1756.FI

Abstract

The highly efficacious live-attenuated 17D yellow fever (YF) vaccine is occasionally associated with rare life-threatening adverse events. Modified vaccinia virus Ankara (MVA), a non-replicating poxvirus, has been used as a vaccine platform to safely deliver various antigens. A MVA-based YF vaccine (MVA-BN-YF) was tested with and without a non-mineral oil adjuvant in a hamster model of lethal YF disease and protective efficacy of this vaccine was compared with the 17D vaccine. The vaccine candidate MVA-BN-YF generated a protective response in hamsters infected with YFV that was comparable to protection by the live 17D vaccine. Similar levels of neutralizing antibody were observed in animals vaccinated with either vaccine alone or vaccine with adjuvant. Significant improvement in survival, weight change, and serum alanine aminotransferase levels were observed in vaccinated hamsters when administered 42 and 14 days prior to challenge with Jimenez YF virus (YFV). Neutralizing antibodies induced by MVA-BN-YF were transferred to naïve hamsters prior to virus challenge. Passive administration of neutralizing antibody 24 h prior to virus infection resulted in significantly improved survival and weight change. A trend toward reduced liver enzyme levels was also observed. MVA-BN-YF, therefore, represents a safe alternative to vaccination with live-attenuated YFV.

Authors+Show Affiliations

Institute for Antiviral Research, Utah State University, Logan, UT, United States.Bavarian Nordic GmbH, Martinsried, Germany.Bavarian Nordic GmbH, Martinsried, Germany.Bavarian Nordic GmbH, Martinsried, Germany.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

30116244

Citation

Julander, Justin G., et al. "Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model." Frontiers in Immunology, vol. 9, 2018, p. 1756.
Julander JG, Testori M, Cheminay C, et al. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model. Front Immunol. 2018;9:1756.
Julander, J. G., Testori, M., Cheminay, C., & Volkmann, A. (2018). Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model. Frontiers in Immunology, 9, 1756. https://doi.org/10.3389/fimmu.2018.01756
Julander JG, et al. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model. Front Immunol. 2018;9:1756. PubMed PMID: 30116244.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model. AU - Julander,Justin G, AU - Testori,Marco, AU - Cheminay,Cédric, AU - Volkmann,Ariane, Y1 - 2018/08/02/ PY - 2018/04/18/received PY - 2018/07/16/accepted PY - 2018/8/18/entrez PY - 2018/8/18/pubmed PY - 2019/10/8/medline KW - 17D KW - hamster KW - modified vaccinia virus Ankara KW - neutralizing antibodies KW - passive immunization KW - yellow fever SP - 1756 EP - 1756 JF - Frontiers in immunology JO - Front Immunol VL - 9 N2 - The highly efficacious live-attenuated 17D yellow fever (YF) vaccine is occasionally associated with rare life-threatening adverse events. Modified vaccinia virus Ankara (MVA), a non-replicating poxvirus, has been used as a vaccine platform to safely deliver various antigens. A MVA-based YF vaccine (MVA-BN-YF) was tested with and without a non-mineral oil adjuvant in a hamster model of lethal YF disease and protective efficacy of this vaccine was compared with the 17D vaccine. The vaccine candidate MVA-BN-YF generated a protective response in hamsters infected with YFV that was comparable to protection by the live 17D vaccine. Similar levels of neutralizing antibody were observed in animals vaccinated with either vaccine alone or vaccine with adjuvant. Significant improvement in survival, weight change, and serum alanine aminotransferase levels were observed in vaccinated hamsters when administered 42 and 14 days prior to challenge with Jimenez YF virus (YFV). Neutralizing antibodies induced by MVA-BN-YF were transferred to naïve hamsters prior to virus challenge. Passive administration of neutralizing antibody 24 h prior to virus infection resulted in significantly improved survival and weight change. A trend toward reduced liver enzyme levels was also observed. MVA-BN-YF, therefore, represents a safe alternative to vaccination with live-attenuated YFV. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/30116244/Immunogenicity_and_Protection_After_Vaccination_With_a_Modified_Vaccinia_Virus_Ankara_Vectored_Yellow_Fever_Vaccine_in_the_Hamster_Model_ L2 - https://doi.org/10.3389/fimmu.2018.01756 DB - PRIME DP - Unbound Medicine ER -